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n 2004, about 3 million people 
died of AIDS [1]. Because sexual 
intercourse accounts for the 
vast majority of HIV transmissions 
worldwide, it is important to 
understand the events that occur in 
the genital or rectal mucosa during 
transmission. Here we dissect a 
number of factors in the transmitter 
and recipient that are relevant before, 
during, and after transmission. We 
weigh the evidence suggesting that the 
transmitted virus differs from the virus 
that predominates in the transmitter. 
We discuss the prospect for protection 
by innate and adaptive immune 
mechanisms at mucosal surfaces as 
well as by locally applied inhibitors of 
viral replication, microbicides. A better 
understanding of sexual transmission 
will enable more rational designs 
of vaccines and microbicides and 
potential combinations of the two.
Transmitting Host, Infectiousness, 
and Transmitted Virus
Early studies estimated the rate of 
sexual HIV transmission to one 
infection per 1,000–2,000 coital acts. 
New data indicate that the rate varies 
widely with the phase of the infection, 
and is more than 10-fold higher 
during acute infection [2,3]. Thus, 
interventions early in infection that 
reduce transmission might have the 
greatest impact on the epidemic.
It is still not clear whether HIV 
transmission is mediated mainly by 
cell-free virus or by infected cells. 
Both forms of virus are present in 
human semen and vaginal ﬂ  uids [4]. 
What immune responses will protect 
may depend on whether mainly virus 
particles or infected cells mediate 
infection. Neutralization by antibodies 
is less efﬁ  cient against cell- than virion-
mediated infection [5]. Thus, results 
obtained with cell-free virus in animal 
vaccine and microbicide experiments 
may not allow extrapolation to 
protection against cell-associated virus 
[6].
Knowledge of the histological 
sources and properties of virus 
from semen and vaginal ﬂ  uids 
is incomplete. The viral load in 
genital ﬂ  uids is more variable, 
and in untreated individuals 
generally lower, than in blood. The 
compartmentalization [4] promotes 
local evolutionary viral divergence. 
In the genital tract of HIV-infected 
females, virus originates from the 
cervix and its associated lymphatic 
tissue, as well as from menstrual blood, 
but virus can also be recovered from 
the vagina of women who have had 
hysterectomies [4]. Semen of HIV-
positive men contains both infected 
macrophages and lymphocytes [4]. In 
simian immunodeﬁ  ciency virus (SIV)-
infected male macaques, most of the 
virus in the genital tract is associated 
with the epididymides, but ejaculates 
from vasectomized men, and pre-
ejaculatory ﬂ  uid, can be infectious [4]; 
10%–20% of men with undetectable 
blood viral load due to antiretroviral 
(ARV) therapy have detectable virus in 
the genital tract [4]. The explanation 
may be that HIV replicates in 
the genital tract, for example in 
macrophages that reside there. 
Despite this compartmentalization, 
viral strains used experimentally in 
vitro and in animal models have been 
isolated from sources such as brain, 
lung, or peripheral blood, usually 
many years after transmission. Such 
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Five Landmark Papers on the 
Virus and Host during Sexual 
Transmission
1. Wawer et al. [2]. This article 
demonstrates that the rate of HIV 
transmission is highest during early 
infection. Thus, interventions targeting 
early infection may have the greatest 
impact on curbing the epidemic. 
2. Shattock and Moore [8]. This review 
discusses the concept of microbicides 
against the background of the 
receptors and cells involved in the 
mechanism of sexual transmission of 
HIV. 
3. Miller et al. [17]. This study describes 
events in the mucosa and lymphatic 
tissue from hours to days after 
vaginal exposure of macaques to 
SIV, identifying a small window of 
opportunity for vaccines, microbicides, 
or other interventions to prevent or 
control infection.
4. Tsai et al. [20]. This paper shows that 
with the right timing and duration, 
systemic administration of ARV can 
prevent infection from becoming 
established. 
5. Kozlowski and Neutra [21]. This review 
discusses the particular demands on 
mucosal immunity in attempts to 
prevent HIV transmission, and how 
such immunity may be elicited.
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virus may differ from genital-tract virus 
in the transmitter and from the early 
outgrowth virus in the recipient.
In a Ugandan study of HIV-
serodiscordant couples (i.e., one 
partner is HIV-infected and the other 
not), plasma viral load correlated 
with the risk of HIV transmission: 
ARV treatment that reduced the 
viral load in blood to less than 1,000 
RNA copies per milliliter seemed to 
reduce transmission [2]. The relative 
contribution of blood-derived virus to 
the infectiousness of men and women 
would affect the preventive impact of 
ARVs. That impact may be deﬁ  ned in 
an ongoing trial [7] that compares the 
effectiveness of two ARV therapies at 
reducing sexual transmission in HIV-
serodiscordant couples.
Other sexually transmitted diseases 
(STDs) increase the amount of virus 
in the genital ﬂ  uids of the transmitter, 
thereby raising transmission rates, 
particularly from men to women. 
STDs can increase the number of 
infected lymphocytes in the mucosa 
and enhance virus expression through 
immune activation [3,4].
Infectiousness of the transmitter is 
thus a composite result of viral load in 
genital ﬂ  uids, the tropism of the virus 
(which can be ascertained in vitro), 
and the in vivo infectivity of that virus 
(which may be difﬁ  cult to measure 
in vitro). Viral escape both from 
neutralization and cellular immunity 
may modulate the phenotype of the 
virus, including its transmissibility. 
Hence there may be several levels 
of selection, or bottlenecks, in the 
transmitter before virus reaches 
the recipient, expands, and can be 
detected (Table 1).
Susceptibility of Host and 
Properties of Newly Transmitted 
Virus
After deposition of the virus on the 
recipient mucosa, the outcome is 
affected by properties of the virus: its 
DOI: 10.1371/journal.pmed.0030079.g001
Figure 1. Early Events during Sexual 
Transmission of HIV
From top to bottom: The epithelial lining of 
the vagina forms an efﬁ  cient barrier to viral 
penetration when intact. Cervical mucus may 
serve to strengthen this barrier by physically 
trapping virions [25]. HIV crosses the epithelial 
barrier either because of epithelial damage 
(e.g., microabrasions and traumatic breaches 
or lesions caused by STDs), or capture by intra-
epithelial DCs that convey the virus to target 
cells deeper in the mucosa [9]. In the lumen 
of the vagina, continuous with the cervical 
canal, virions with two kinds of tropism are 
illustrated: (i) X4 virus (orange) uses the 
co-receptor CXCR4 (rarely found early after 
transmission) and (ii) R5 virus (green) utilizing 
the co-receptor CCR5 (preferentially found 
early after transmission). Why R5 virus comes 
to dominate in the newly infected host is not 
known; it may reﬂ  ect preferential ampliﬁ  cation 
at a stage after transmission (not shown) [26]. 
To the left, an R5 virion is shown bound to an 
embedded DC, which has CD4, CCR5, and C-
type lectin receptors on its surface, all of which 
can interact with the surface glycoprotein of 
the virus. The DC may merely capture X4 or R5 
virus and carry it across the epithelial barrier or 
get infected by R5 virus and produce progeny 
virus (virus budding from the cell surface is 
shown as half-circular sections studded with 
grey Env spikes) [9]. To the right, an R5 virion 
binds to and infects a T helper lymphocyte, 
which has both CD4 and CCR5 on its surface. 
Virus that has penetrated into the epithelium 
is also shown to infect a macrophage. Arrows 
indicate how virus infects the ﬁ  rst target cells 
and how progeny virus or DCs then migrate 
via the afferent lymphatics to reach the lymph 
nodes. Here, further ampliﬁ  cation occurs 
in an environment rich in CD4+ target cells. 
From there, new generations of progeny virus 
cascade to the next level of lymphatic tissue. 
The gut-associated lymphoid tissue provides 
an important reservoir of susceptible cells 
that the virus rapidly decimates (not shown). 
Ultimately, the virus disseminates via efferent 
lymphatics and blood to spleen, brain, liver, 
and lungs. 
(Illustration: Courtesy IAVI Report, Volume 8, 
May–August 2004).
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retention of infectivity while traversing 
the mucus and extracellular matrix, 
its afﬁ  nity for entry receptors, the 
fusogenicity of its Env protein, and 
the efﬁ  ciency of its interaction with 
dendritic cells (DCs) that can promote 
virus spread to, and ampliﬁ  cation 
in, CD4+ T cells, locally and possibly 
at distant sites (Figure 1) [8,9]. 
Superimposed upon this, there are 
likely to be strong selective pressures in 
the recipient at later steps, determining 
which virus takes over in the newly 
infected host (Table 1).
STDs make recipients more 
susceptible by breaking down the 
mucosal barrier in the case of genital 
ulcer disease and by increasing the 
number of susceptible cells in the 
mucosa through inﬂ  ammation. 
Bacterial vaginosis—the colonization of 
the vagina by anaerobic bacteria—may 
further enhance the infectivity of 
incoming virus by raising the pH of the 
vaginal ﬂ  uid: a higher pH would lead 
to slower virus inactivation and more 
efﬁ  cient Env-mediated fusion [3,4]. 
Male susceptibility can be reduced by 
two-thirds through adult circumcision 
[10]. It remains to be seen whether 
this is a direct effect on the number 
of target cells, in which the prepuce 
is rich, or an indirect effect on STD 
susceptibility and inﬂ  ammation.
Newly transmitted viruses are likely to 
be more closely related to viruses that 
vaccines must protect against than later-
stage viruses. Such early virus has been 
suggested to have distinct features. 
Early in infection, recipients appear 
to show much less viral diversity than 
the average infected person [11,12]. 
Derdeyn et al. investigated eight newly 
infected people from a cohort of more 
than 1,000 continual exposures among 
discordant couples. These recipients 
harbored HIV strains (seven clade C 
and one clade G) with notably short 
V1 and V2 variable regions of the 
viral envelope glycoprotein gp120, 
which therefore had relatively few 
glycosylation sites. This could affect 
the recognition of the Env complex by 
neutralizing antibodies. Indeed, virus 
isolated from the recipient showed 
greater sensitivity to neutralization by 
sera from the transmitting individual 
than did virus from the transmitter 
[11]. The explanation may be either 
that neutralization-sensitive variants 
with more accessible receptor-binding 
domains pre-exist in the transmitter 
and are selectively transmitted, or 
that in the absence of neutralization 
pressure in the new host variants like 
this rapidly arise and expand.
However, such Env-selection 
does not seem to occur in clade-B 
transmission in intravenous-drug-
abusing or homosexual cohorts [13]. It 
is uncertain whether this discrepancy 
would relate to modes of transmission, 
HIV subtypes, or viral properties that 
evolve as the proportion of acutely 
infected individuals changes in the 
course of the epidemic [13]. This is 
a topic of intensifying study that may 
shed new light on viral transmissibility.
Studies of highly exposed uninfected 
men from a cohort in Amsterdam 
failed to identify a unifying explanation 
for what prevented infection [14]. 
Different host factors may contribute to 
resistance to HIV-1 infection, including 
innate immunity. Lymphocytes from 
some of the men showed reduced R5 
HIV infection in vitro due to autocrine 
secretion of CCL chemokines. 
Lymphocytes from other seronegative 
persons in the cohort also showed 
poor proliferative responses in vitro. A 
subset of individuals had low numbers 
of memory effector T cells and a low 
activation level of CD4+ T cells, thereby 
presenting few target cells for the 
virus [15]. The same magnitude and 
breadth of HIV-speciﬁ  c cytotoxic T 
cell responses were detected among 
exposed people whether they remained 
uninfected or later seroconverted 
[15]. Qualitative differences between 
the cellular immune responses may 
nevertheless render some protective 
and others merely indicative of 
exposure. This is another very active 
area of investigation that may deﬁ  ne 
immune correlates of protection 
against HIV infection.
Establishment of Infection 
in the Vagina or Rectum 
at a Histological Level
Experiments using cervical explants 
indicate that an intact mucosal 
epithelium forms an impenetrable 
barrier to HIV [8]. It is difﬁ  cult to 
judge whether the barrier is equally 
impenetrable and the trafﬁ  cking of 
cells across it similar when the tissue 
is perfused by circulating blood in 
the living organism. But there appear 
to be additional impediments to 
HIV replication, since replication is 
restricted even when the mucosal layer 
is breached by microabrasions.
In macaque models of SIV infection, 
the viral dose is higher than in most 
human exposures, perhaps higher 
even than when the transmitter is at 
the peak of primary-infection viral 
load. However, in this model the 
ﬁ  rst infectious events in the mucosa 
occur within hours. During the ﬁ  rst 
days, there is some dissemination 
beyond the mucosa: this may be 
mediated through lymphovascular 
anastomoses or trafﬁ  cking of the virus 
by DCs [9]. It usually takes 4–6 days 
for the infection to become systemic. 
The establishment of a productive 
infection in the animal seems to 
depend critically on the continual 
seeding from a founder population of 
infected, ostensibly resting, memory 
CD4+ T cells in the genital tract. 
From these, the infection further 
disseminates to local lymph nodes and 
then to secondary lymphatic tissue, 
eventually becoming systemic [16,17]. 
The escalation from one level to the 
Table 1. Potential Selection Pressures on Virus during Sexual Transmission
Host Viral Properties
Transmitter (has adaptive immune 
response to own virus)
Capacity to produce high viral loads, particularly in acute infection
High replication in genital tract
Retention of infectivity in genital ﬂ  uids
Recipient (in the absence of 
immunization: only has innate immunity 
at the time of exposure)
Resistance to innate immune factors
Interaction with DCs affecting survival of the virus and its transfer 
to T cells
Efﬁ  ciency of attachment, receptor–co-receptor usage, and 
fusogenicity
Ability to disseminate
Capacity to expand in lymphoid tissue and establish infection
DOI: 10.1371/journal.pmed.0030079.t001
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next has been likened to a broadcast 
effect, each wave involving new bursts 
of ampliﬁ  cation of the virus (Figure 
1) [16,17]. Virus is found in the gut-
associated lymphoid tissue by day 
6–7, when only the rudiments of an 
SIV-speciﬁ  c immune response are 
detectable. Within 14 days of SIV 
infection, effector memory CD4+ 
cells in the intestinal lamina propria 
are selectively and permanently 
depleted [18]. It is plausible that many 
exposures to the virus that do not lead 
to established infections involve local, 
transitory viral replication. And when 
the infection does get established, 
scattered foci of founder cells arise 
from only a small fraction of the 
inoculum. The delay of up to six days 
before systemic replication, even in 
this high-dose model, and in spite of 
the rapid dissemination to draining 
lymph nodes, suggests that a crucial 
level of replication in local lymphoid 
tissues is required for establishment 
of infection. Below this level, the 
infection may abort. This scenario 
implies that prevention is still possible 
during a short period in which the 
virus is actively replicating. If this 
simian model accurately reﬂ  ects the 
events in human transmission, it can 
help elucidate exactly what must be 
achieved in prevention.
Even though retroviral infection 
is seen as irreversible because of the 
integration of the pro-virus into the 
host-cell genome, the dynamic model 
of seeding and dissemination described 
above gives reason to modify that view: 
at the level of the organism, abortive 
HIV infections may be frequent. 
Sterilizing immunity would not need to 
achieve more than what hypothetically 
happens spontaneously in many cases 
when a seeding population is too 
small to sustain the cascading events. 
Consequently, there could be a window 
of opportunity early in infection 
for a potent, local, vaccine-induced 
immune response or a microbicide to 
prevent or dampen viral replication 
in the ﬁ  rst host cells and thereby to 
increase the chances that subsequent 
immune mechanisms abort the nascent 
infection. This is also consistent with 
protection of macaques through 
systemic administration of inhibitors 
of reverse transcription or of entry 
(CCR5 ligand CMPD167), if treatment 
is started 24–48 hours after exposure 
to SIV or SHIV (HIV–SIV hybrids) and 
continued for 10–28 days [19,20].
Mucosal Immunity and Protection 
by Vaccines/Microbicides
What interventions can block viral 
transmission? As we have outlined, high 
viral load, speciﬁ  cally in genital ﬂ  uids, 
raises the risk of HIV transmission. 
Thus, if vaccine-induced cell-mediated 
immunity (CMI) substantially reduced 
the viral load in genital ﬂ  uids during 
primary infection, the vaccinee would 
not become a high-risk transmitter. 
Such a herd-immunity effect would 
reduce transmission by either gender. 
The majority of vaccines currently in 
clinical trials are aimed at eliciting 
CMI. However, CMI responses in the 
genital mucosa are largely unexplored 
because they are difﬁ  cult to measure 
[4]. Intranasal immunization is the 
most efﬁ  cient way to elicit genital 
tract immune responses in several 
animal models, although this approach 
potentially poses safety problems: 
Bell’s palsy was observed following 
intranasal immunization with an 
inﬂ  uenza vaccine formulated with 
heat-labile Escherichia coli enterotoxin 
as an adjuvant [21,22]. The lower 
genital tract is not a good inductive site, 
but immunogens delivered vaginally 
quickly reach the upper reproductive 
tract, providing an effective localized 
booster immunization [21,22]. 
However, genital immunization could 
induce inﬂ  ammation, which would 
enhance the risk of HIV infection. 
It is also noteworthy that systemic 
immunization on its own can induce 
mucosal immunity: papilloma virus 
infection of the anogenital mucosa can 
be prevented by an intramuscularly 
delivered vaccine [23]. The humoral 
component of that immunity is likely to 
be transudated IgG [22].
As complicating factors, the CD8+ 
cell numbers, cytokine, and possibly 
antibody secretion in the female 
genital tract vary with the menstrual 
cycle [4,22]. Furthermore, vaccine 
protection needs to be effective in the 
presence of co-factors such as STDs, 
damaged mucosa (microabrasions), 
and vaginosis. STD treatment may 
enhance the effectiveness of vaccines 
and/or microbicides and should be 
further explored in clinical trials [4,8].
Neutralizing antibodies have been 
shown to provide protection through 
passive immunization of animals 
[24], but their elicitation through 
active immunization has so far been 
the greatest hurdle in HIV vaccine 
development. Furthermore, the titers of 
neutralizing antibodies in vivo that are 
required to block vaginal transmission 
of HIV are many orders of magnitude 
greater than those measured in 
infected people, which in turn are 
much greater than any that have been 
induced by active immunization [24]. 
The problem of eliciting protective 
humoral immunity seems formidable. 
However, both mucosal and circulating 
antibodies to HIV may be beneﬁ  cial 
through neutralization as well as other 
mechanisms [21].
HIV induces strong IgG responses in 
blood and in secreted body ﬂ  uids (e.g., 
nasal, rectal, and vaginal secretions; 
semen, saliva, and tears). In contrast, 
IgA responses to HIV are low in these 
body ﬂ  uids that typically contain 
high IgA levels. Importantly, human 
genital-tract secretions (semen and 
cervico-vaginal ﬂ  uids) contain IgG 
derived largely from plasma. Thus, 
if systemic immunization resembles 
natural HIV infection, it would 
February 2006  |  Volume 3  |  Issue 2  |  e79
Box 1. Future Directions for 
Research
•  Study transmission risk and viral load in 
plasma and genital secretions.
•  Correlate cell-free and cell-associated 
viral load in genital secretions to risk of 
transmission.
•  Investigate effect of vaccines on peak 
viral loads.
• Deﬁ  ne the impact of co-pathogens 
(especially STDs) and hormones 
on vaccine and/or microbicide 
effectiveness in efﬁ  cacy trials.
•  Weigh the contribution of HIV–DC 
interaction to transmission in animal 
experiments.
•  Isolate HIV from genital secretions.
•  Identify mechanisms that restrict HIV 
replication in genital tract explants, 
including innate immunity.
•  Evaluate mucosal boosting after 
systemic priming in order to induce 
genital immune responses.
•  Evaluate inclusion of HIV-1 antigens, 
especially Env protein, as immunogens 
in microbicides.
•  Improve mucosal immunogenicity—
e.g., by incorporating Toll-like receptor 
ligands in vaccines/microbicides.PLoS Medicine  |  www.plosmedicine.org 0185
preferentially yield high levels of IgG 
in the genital tract. By combining 
mucosal (oral, rectal, and intranasal) 
with systemic immunization, one 
might achieve even higher levels of 
IgG in all compartments [21,22]. To 
conclude, it may be feasible to induce 
strong humoral responses to HIV in 
the genital tract secretions, but how to 
achieve efﬁ  cient neutralization remains 
unknown.
The lack of efﬁ  cient vaccines that 
yield mucosal protection against HIV 
points to the potential beneﬁ  ts of 
microbicides and oral prophylaxis 
regimens, several of which are currently 
under development [8,9]. First, a 
microbicide may be used as a substitute 
for mucosal neutralizing antibodies. 
This strategy could be combined with 
a vaccine that elicits efﬁ  cient cellular 
immunity. Together they may render 
the population of infected founder cells 
too small for the infection to establish 
itself. Second, and more speculatively, 
HIV-1 immunogens, especially 
forms of the Env protein, added 
into microbicides, might improve 
mucosal immune responses: while they 
may not be effective by themselves, 
they may provide valuable mucosal 
boosts after systemic vaccination. To 
enhance immunogenicity, Toll-like 
receptor ligands might be added to 
the immunogen in the microbicide. 
A serious risk, however, is that this 
approach could yield inﬂ  ammation 
and enhanced susceptibility to HIV-1 
infection. Obviously, rigorous pre-
clinical animal experimentation would 
be required to address such issues. 
It is also possible that microbicides, 
particularly those that target the virus, 
when applied vaginally or rectally 
by infected individuals, would lower 
their infectiousness by reducing the 
infectivity of the virus exposed on their 
mucosae. 
Conclusion
Important questions about sexual 
transmission of HIV remain (Box 1). 
Improved knowledge of host factors 
in both the transmitter and recipient 
that affect transmission will be crucial. 
It is essential to characterize HIV in 
genital secretions in terms of qualitative 
and quantitative differences between 
compartments and viral evolution 
during transmission. In conjunction 
with the exploration of increased 
microbicide efﬁ  ciency, strategies 
for eliciting mucosal immunity will 
need to be pursued. In any case, 
both microbicides and vaccination 
would be compatible with condom 
use and risk-reducing behavior, which 
remain essential. Taken together, 
these measures, largely deriving from 
a biological understanding of the 
major mode of transmission, might 
have synergistic effects in curbing the 
pandemic.  
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